Showing 2631 results
- https://www.novartis.com/news/media-releases/novartis-cosentyx-first-and-only-il-17a-inhibitor-potentially-modify-course-psoriasisNew data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before…
- https://www.novartis.com/news/media-releases/new-analysis-shows-novartis-entresto-improves-glycemic-control-reduced-ejection-fraction-heart-failure-patients-diabetesNew post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced…
- https://www.novartis.com/news/media-releases/novartis-kisqali-ribociclib-lee011-receives-fda-approval-first-line-treatment-hrher2-metastatic-breast-cancer-combination-any-aromatase-inhibitorApproved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] …
- https://www.novartis.com/news/media-releases/sandoz-announces-winners-inaugural-healthcare-access-challenge-sandoz-hackThree winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines. Winning ideas…
- https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-almost-all-psoriasis-patients-rapidly-regain-skin-clearance-following-treatment-pauseNew analysis shows 94% of patients on Cosentyx® regained PASI 75, with up to 80% of patients regaining PASI 90 to 100 after only 16 weeks of retreatment[1] Cosentyx has shown superior and…
- https://www.novartis.com/news/media-releases/new-data-demonstrate-sandoz-proposed-biosimilar-adalimumab-has-equivalent-efficacy-reference-medicineSandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*Comprehensive development program show potential of GP2017…
- https://www.novartis.com/news/media-releases/novartis-aktionare-genehmigen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsratsAktionäre genehmigen für 2016 die 20. Dividendenerhöhung in Folge auf CHF 2,75 pro Aktie (+2%) - dies entspricht einer Rendite von 3,5% und einer Ausschüttungsquote von circa 69% des Free Cashflow…
- https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meetingShareholders approve 20th consecutive dividend increase to CHF 2.75 (+2%) per share for 2016; representing a 3.5% yield and approximately 69% payout of free cash flow Dr. Joerg Reinhardt…
- https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-annuelleLes actionnaires approuvent la 20e hausse consécutive du dividende, à CHF 2,75 (+2 %) par action au titre de l'exercice 2016. Cela représente un rendement de 3,5 % et une distribution du free cash-…
- https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-tafinlar-mekinist-braf-positive-non-small-cell-lung-cancer-nsclc-patientsIf approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation CHMP opinion based on positive data from pivotal study of patients…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 264
- › Next page